Background/Aim: Comorbid depression often occurs in chronic renal failure patients on hemodialysis (HD). Reduced serotonin (5-HT) function is implicated in the pathophysiology of depression. Methods: Comorbid depression and different clusters of depressive symptoms were assessed in 79 male HD patients and 35 male depressed psychiatric patients. Platelet 5-HT concentration (a peripheral model for the central serotonergic neurons) was determined in all patients and 80 male healthy controls. Results: Comorbid depression occurred in 50 out of 79 HD patients. Depressed psychiatric patients and depressed HD patients had higher scores of anxiety, retardation, and cognitive symptoms than nondepressed HD patients. Platelet 5-HT concentration was lower in depressed or nondepressed HD patients than in healthy controls, or in depressed patients. Higher platelet 5-HT content was found in depressed psychiatric patients with depressive clusters than in all other patients. Among HD patients, anxious HD patients had a higher platelet 5-HT concentration than HD patients without anxiety symptoms. Conclusions: Comorbid depression occurred in 63% of HD patients. Dialyzed patients had decreased platelet 5-HT concentration, regardless of the occurrence of comorbid depression. Higher platelet 5-HT concentration was related to anxiety symptoms in HD patients. Our data suggest that platelet 5-HT concentration might be a suitable marker for anxiety symptoms in dialyzed patients.

Keywords:
Chronic renal patients, Comorbid depression, Clusters of depressive symptoms, Depressed patients, Hemodialysis, Platelet serotonin
1.
Levy NB: Renal failure, dialysis, and transplantation; in Robinson RG, Yates WR (eds): Psychiatric Treatment of the Medically Ill. New York, Dekker, 1999, pp 141–153.
2.
Pivac N, Mück-Šeler D, Barišić I, Jakovljević M, Puretić Z: Platelet serotonin concentration in dialysis patients with somatic symptoms of depression. Life Sci 2001;68:2423–2433.
3.
Kimmel PL: Depression in patients with chronic renal disease. What we know and what we need to know. J Psychosom Res 2002;53:951–956.
4.
Finkelstein FO, Finkelstein SH: Depression in chronic dialysis patients: Assessment and treatment. Nephrol Dial Transplant 2000;15:1911–1913.
5.
Davis B, Krug D, Dean RS, Hong BA: MMPI differences for renal, psychiatric, and general medical patients. J Clin Psychology 1990;46:178–184.
6.
Stahl SM: Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998;51:215–235.
7.
Camacho A, Dimsdale JE: Platelets and psychiatry: Lessons learned from old and new studies. Psychosom Med 2000;62:326–336.
8.
Andres AH, Rao MA, Ostrowitzki S, Enzian W: Human brain cortex and platelet serotonin2 receptor binding properties and their regulation by endogenous serotonin. Life Sci 1993;52:313–321.
9.
Mezzano S, Kunick M, Olavarria F, Ardiles L, Aranda E, Mezzano D: Decreased platelet counts and decreased platelet serotonin in poststreptococcal nephritis. Nephron 1995;69:135–139.
10.
Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M: Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 1996;83:351–361.
11.
Parbtani A, Frampton G, Cameron JS: Platelet and plasma serotonin concentrations in glomerulonephritis. Part 2. Clin Nephrol 1980;14:112–123.
12.
Kanai K, Ishii Y, Maezawa A, Yano S, Naruse T: Serotonin metabolism in patients undergoing hemodialysis. Clin Nephrol 1996;45:244–249.
13.
Mück-Šeler D, Jakovljević M, Pivac N: Platelet 5-HT concentrations and suicidal behavior in recurrent major depression. J Affect Disord 1996;39:73–80.
14.
Pivac N, Jakovljević M, Mück-Šeler D, Brzović Z: Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry Res 1997;73:123–132.
15.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
16.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
17.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
18.
Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, 1976.
19.
Mück-Šeler D, Jakovljević M, Deanović Ž: Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord 1991;23:157–164.
20.
Mück-Šeler D, Pivac N, Šagud M, Jakovljević M, Mihaljević-Peleš A: The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1235–1243.
21.
Sole MJ, Madapallimattam A, Baines AD: An active pathway for serotonin synthesis by renal proximal tubules. Kidney Int 1986;29:689–694.
22.
Qureshi AR, Lindholm B, Garcia E, Groth CG, Bergstrom J: Tryptophan and its metabolites in patients on continuous ambulatory peritoneal dialysis and following renal transplantation. Nephrol Dial Transplant 1994;9:791–796.
23.
Šebekova K, Raučinova M, Dzurik R: Serotonin metabolism in patients with decreased renal function. Nephron 1989;53:229–232.
24.
Shiah I-S, Ko HC, Lee JF, Lu RB: Platelet 5-HT and plasma HMPG levels in patients with bipolar I and bipolar II depressions and normal controls. J Affect Disord 1999;52:101–110.
25.
Mück-Šeler D, Pivac N, Jakovljević M, Šagud M, Mihaljević-Peleš A: Platelet 5-HT concentration and comorbid depression in war veterans with or without posttraumatic stress disorder. J Affect Disord 2003;75:171–179.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.